EMA Recommends Extension of Indications for Serplulimab By Ogkologos - April 22, 2026 209 0 Facebook Twitter Google+ Pinterest WhatsApp New indications concern the treatment of patients with oesophageal squamous cell carcinoma and non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Why I Choose to Live With Gratitude During Metastatic Breast Cancer December 29, 2022 Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with... December 18, 2025 Shelter Puppies Got A Private Tour Of The Georgia Aquarium March 31, 2020 Five Questions With…Jim. April 28, 2022 Load more HOT NEWS Telisotuzumab Vedotin Associated with Durable Responses in c-Met Protein–Overexpressing Non-Squamous EGFR-wild-type... Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate... A Vaccine to Treat Non-Hodgkin Lymphoma Advancing in Clinical Trials Tecartus Becomes First CAR T-Cell Therapy Approved for Adults with ALL
